Acquires marketing rights to Columbia Labs' Replens for the U.S. under a licensing agreement announced Dec. 6. Columbia will continue to manufacture the OTC vaginal moisturizer. A similar U.S. licensing agreement with Schering-Plough covering Columbia's women's health care products line was terminated in 1990 less than a year.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth